Detalles de la búsqueda
1.
Mesothelioma: Pleural, Version 1.2024.
J Natl Compr Canc Netw
; 22(2): 72-81, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38503043
2.
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.
Future Oncol
; 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38357801
3.
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Cancer
; 129(9): 1319-1350, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36848319
4.
Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer.
Oncologist
; 28(8): e625-e632, 2023 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37085156
5.
Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
Cancer Immunol Immunother
; 72(6): 1727-1735, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36640189
6.
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy.
Cancer Immunol Immunother
; 72(7): 2005-2013, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36738310
7.
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy.
Cancer Immunol Immunother
; 72(7): 2067-2074, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36795122
8.
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
J Natl Compr Canc Netw
; 21(11): 1164-1171.e5, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37935100
9.
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
J Natl Compr Canc Netw
; 21(4): 340-350, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37015337
10.
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(9): 961-979, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37673108
11.
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(5): 497-530, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35545176
12.
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
N Engl J Med
; 378(22): 2093-2104, 2018 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29658845
13.
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.
Cancer Immunol Immunother
; 70(10): 2761-2769, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33625533
14.
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
J Natl Compr Canc Netw
; 19(8): 915-921, 2021 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878726
15.
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
J Natl Compr Canc Netw
; 19(3): 254-266, 2021 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33668021
16.
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Lancet Oncol
; 21(2): 261-270, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31838015
17.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother
; 69(7): 1189, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32347358
18.
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Cancer Immunol Immunother
; 69(11): 2403-2408, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32728772
19.
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort.
Cancer Immunol Immunother
; 69(7): 1177-1187, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140762
20.
Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
BMC Cancer
; 20(1): 383, 2020 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32375706